Summary
Piroxicam, a nonsteroidal antiinflammatory drug, was given to 62 dogs bearing naturally occurring tumors in a phase I clinical trial. Dose escalation was performed, with oral doses ranging from 0.5 mg/kg every 48 h (q48h) to 1.5 mg/kg q48h being tested. Dose-limiting gastromestinal irritation/ulceration occurred in all four animals that received 1.5 mg/kg q48h. The maximum tolerated dose was 1 mg/kg q48h. Subclinical renal papillary necrosis occurred in two dogs (initial dosages, 1 and 1.5 mg/kg q48h, respectively). Following dose escalation, an additional group of dogs was treated with 0.3 mg/kg piroxicam q24h per os, the accepted canine dosage prior to this trial. Inclusion of this treatment group enabled evaluation of the toxicity of and tumor response to a daily dosage regimen. No complete remissions occurred in this trial. Partial remission was documented in three of ten dogs exhibiting transitional-cell carcinoma, in three of five animals bearing squamous-cell carcinoma, in one of three dogs displaying mammary adenocarcinoma, and in the one dog that exhibited a transmissible venereal tumor. The results of this study support the additional evaluation of piroxicam in a phase II clinical trial in dogs bearing naturally occurring tumors.
Similar content being viewed by others
References
Ando GA, Lombardino JG (1983) Piroxicam — a literature review of new results from laboratory and clinical studies. Eur J Rheumatol Inflamm 6: 3
Breau JL, Morere JF, Israel L (1989) Regression and inhibition of the growth of human lung metastases induced by piroxicam, an inhibitor of prostaglandin synthesis. Bull Cancer 76: 321
Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310: 563
Hobbs DC (1983) Pharmacokinetics of piroxicam in man. Eur J Rheumatol Inflamm 6: 46
Hobbs DC, Twomey TM (1981) Metabolism of piroxicam by laboratory animals. Drug Metab Dispos 9: 114
Howard EB, Sawa TR, Nielsen SW, Kenyon AJ (1969) Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma. Vet Pathol 6: 146
Mitnick PD, Klein WJ (1984) Piroxicam-induced renal disease. Arch Intern Med 144: 63
Nigro ND, Bull AW, Boyd ME (1986) Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 77: 1309
Owen LN (1980) TNM classification of tumors in domestic animals, 1st edn. World Health Organization, Geneva
Pfizer Inc. (1978). Results of basic research on CP-16,171 (piroxicam). Information booklet. Pfizer Inc., Laboratories Division, New York
Pollard M, Luckert PH (1984) Effect of piroxicam on primary intestinal tumors induced in rats byN-methylnitrosourea. Cancer Let 25: 117
Pollard M, Luckert PH (1989) Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 49: 6471
Pollard M, Luckert PH, Schmidt MA (1983) The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 21: 57
Reddy BS, Maruyama H, Kelloff G (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340
Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G (1990) Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug, withd,l-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in the diet. Cancer Res 50: 2562
Ross DS, Bitzer D, Roy T, Murphy JE (1988) Piroxicam inhibits the growth of an adenocarcinoma isograft in Fischer rats. J Surg Res 45: 249
Roth SH, Bennett RE (1987) Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med 147: 2093
Twomey TM, Bartolucci SR, Hobbs DC (1980) Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 183: 104
Wiseman EH, Chang YH, Lombardino JG (1976) Piroxicam, a novel anti-inflammatory agent. Arzneimittelforschung 26: 1300
Author information
Authors and Affiliations
Additional information
This investigation was supported by Pfizer Inc.
Rights and permissions
About this article
Cite this article
Knapp, D.W., Richardson, R.C., Bottoms, G.D. et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother. Pharmacol. 29, 214–218 (1992). https://doi.org/10.1007/BF00686255
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686255